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Abstract  
Background: Several anti apoptotic signals have been recently identified. Aven and 
Survivin are broadly expressed and are conserved in mammalian species. 
 Patients and Methods: 39 AML and 25 ALL were tested. Aven and Survivin 
expression were detected by RT-PCR. DNA fragmentation was carried out  daily after 
treatment. 
.Results: Survivin was expressed (P=0.06) more in AML (74%) than in ALL (52%). 
While, Aven was equally expressed in both leukemias. Patients were categorized into 
3 groups based on DNA fragmentation. Absence of Aven significantly (p‹0.001) 
contributed to DNA fragmentation,but Survivin did not contribute as much. None of 
the concordant both positive Survivin and Aven were in group III (the good 5 day 
fragmentation, (P< 0.001). Survivin was statistically related to CD7 expression 
(P<0.001) in AML only. There was a significant dissociation between Aven and 
Survivin in AML (p=0.03) and near significant dissociation in ALL (p=0.07).    
 
Conclusion: Aven seems to be more important as an inhibitor of apoptosis than 
survivin in acute leukemia. The presence of both confers a survival disadvantage and 
a significantly worse DNA fragmentation pattern suggesting a synergistic inhibition 
of apoptosis. The highly significant relation between CD7 and survivin expression 
might suggest their involvement in a common signal transduction pathway. 
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Introduction 
 
           Both leukaemogenesis and resistance to chemotherapy can be attributed to 
blocks of apoptosis. Inhibitors of apoptosis
 
proteins (IAPs) are originally identified in 
malignant cells & during fetal development (1).In many instances IAP family proteins 
can suppress apoptosis across species barriers (2) implying that these proteins 
evidently target a common mechanism. Six human IAPs have been described
 
so far: 
NAIP, CIAP1, CIAP2, XIAP, survivin and apollon. ( 3-8 ). Although there is some 
evidence that IAPs play an important role in the chemoresistance of leukemia cell 
lines, little is known about their influence on this phenomenon in acute leukemia cells 
of human origin. 
 
         Survivin is an antiapoptotic gene, which is overexpressed in
 
most human tumors 
and involved in mitotic checkpoint control. High levels of survivin expression
 
have 
been associated with cancer progression, drug resistance,
 
poor prognosis, and short 
patient survival (9&10). Recently, silencing of survivin gene by small interfering 
RNAs provide novel approaches for treatment of androgen-independent
 
prostate 
cancer (11), childhood osteogenic sarcoma as well as pancreatic cancer. To date 
several approaches have been taken to target and eliminate IAP function in an attempt 
to re-establish sensitivity, reduce toxicity, and improve efficacy of cancer treatment. 
 
        Aven, a novel apoptosis inhibitor identified in the year 2000 (12) functions 
through binding Bcl-xL and Apaf-1. Aven is broadly expressed and
 
is conserved in 
mammalian species. It suppresses apoptosis induced
 
by Apaf-1 and caspase-9.Clinical 
relevance of aven was studied in acute leukemia in a Turkish population (13). 
 
The aim of the present study is to evaluate survivin & aven expression in acute 
leukemia, and asses their prognostic relevance in acute leukemia patients. 
 
 
 
 
 
 Material and Methods 
     This study included 64 patients with acute leukemia selected from pediatric and 
medical oncology department of the National Cancer Institute of Cairo University in 
the period between 2006 and 2007. These patients were classified as: -
 
Group I: 
    Twenty five patients with de novo ALL, 14 males and 11 females. Their ages 
ranged from 1 to 57years. 
 Group II:  Thirty nine  patients with de novo AML, 26 males and 13 females. Their 
ages ranged between 4 to 60 years. All the collected blood samples of the patients 
were subjected to assessment of the expression of SURVIVIN & AVEN in leukemic 
cells by RT-PCR. All patients of this study were treated according to the institute 
ongoing induction and consolidation regimens. 
METHODS: 
1- SAMPLING: 
       From each patient 3 ml venous blood were obtained by a sterile venipuncture and 
were put in a sterile vaccutainer containing EDTA as anticoagulant. This sample was 
divided as follows: 
1 1.0 ml for RNA extraction and PCR analysis by using QIA amp RNA 
extraction kit. 
2 1.0 ml for performing complete haemogram (Coulter- T 405). 
3 1.0 ml for DNA extraction and gel electrophoresis by using QIA amp DNA 
extraction kit. 
 
2-DETECTION OF SURVIVIN AND AVEN  EXPRESSION (RT-PCR):  
 
  (Using RT-PCR kits: Qiagen (Catalog number: 12110007).Primers for Survivin 
Aven and B actin amplification, all primers were used for each gene (Operon 
primers).  Primer-1 (sense strand primer) for Survivin The survivin mRNA Genbank
 
accession number is NM001168. It had the following sequence: 5'-
ACCAGGTGAGAAGTGAGGGA-3'
 
 
 Survivin  sense strand, scale: 10 nmol. Primer-2 (Anti-sense strand primer) for 
Survivin 5'-AACAGTAGAGGAGCCAGGGA-3'.  Primer-1 (sense strand primer) 
for Aven. The aven mRNA Genbank accession
 
number is AF283508..It had the 
following sequence: 
5'-GATTTCAGTGTCCTCCTTAG-3'
 
Aven  sense strand, scale: 10 nmol.Primer-2 
(Anti-sense strand primer) for Aven 5'-CCTTGCCATCATCAGTTCTC-3'Aven anti-
sense strand, scale:10 nmol. Primers for B actin amplification. The B actin mRNA 
Genbank accession
 
number is NM_001101  Primer-1 (sense strand primer). It had 
the following sequence: 5' TGACGGGGTCACCCACACTG3'.B actin sense strand, 
scale: 10 nmol.  
Primer-2 (Anti-sense strand primer):5' CTAGAAGCATTTGCGGTGGA 3' 
 
   Reverse Transcriptase RT-PCR was carried, 
1- All reaction tubes were transferred to a thermal cycler and incubated at 55ºC for 30 
minutes for c-DNA synthesis then, incubated at 95ºC for 15 minutes to inactivate the 
reverse transcriptase and to completely denaturate the template. 
2- For PCR amplification of Survivin , denaturation: 94ºC for 60 sec,annealing: 59ºC 
for 60 sec, polymerization:  72ºC for 60 sec,final extension  72ºC for 10 min. 
    This was repeated for a total of 32 cycles. 
3-For PCR amplification of Aven ,denaturation: 94ºC for 60 sec.annealing: 60ºC for 
60 sec,polymerization:  72ºC for 60 sec ,final extension  72ºC for 10 min. 
    This was repeated for a total of 32 cycles. 
4- Another set of PCR master mix was used for amplification of B- actin, 
denaturation: 94ºC for 60 sec.annealing: 55ºC for 60 sec. polymerization:  72ºC for 60 
sec.final extension 72ºC for 10 min. 
5- Amplified material was stored at -20ºC until gel electrophoresis was performed. 
The size of the amplified product was read with the use of a DNA marker of different 
molecular weight molecular weight (308bp for Survivin, 252 bp for Aven and 600bp 
for B actin), figure (1-2).  
 4-Detection of apoptosis by agarose gel electrophoresis: (14) 
DNA fragmentation was carried out on daily basis before chemotherapy and 24 hours after the therapeutic dose every day for 5 
times during the initial induction of chemotherapy
. 
    Before chemotherapy and 24 hours after the induction therapy   peripheral blood 
samples were taken from each patient and detection of apoptosis by agarose gel 
electrophoresis was done figure (3). 
                    
5- STATISTICAL ANALYSIS OF THE RESULTS: 
     
Data was analyzed using SPSS win statistical package version 15. Numerical data 
were expressed as mean±standard deviation, median and range. Qualitative data were 
expressed as frequency and percentage.  Chi-square test (Fisher's exact test) was used 
to examine the relation between qualitative variables. For quantitative data, 
comparison between two groups was done using Mann-Whitney test (non-parametric 
test corresponding to student t-test for variables not normally distributed. Comparison 
between 3 groups was done using Kruskal-Wallis test (non-parametric ANOVA test). 
Then by post-Hoc comparison test "Schefe test" was used to compare pairs of groups 
on rank of the variables. Survival analysis was done using Kaplan-Meier method. 
Comparison between two survival curves was done using Log-rank test. P-value ≤ 
0.05 was considered significant and less than 0.001 considered as highly significant.                                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RESULTS 
 
         The aim of this study was to assess survivin and aven expression levels with 
regard to the potential role of these genes as a prognostic marker in acute leukemias, 
the most common malignancy. Survivin expression in acute leukemia 42 out of 64 
(66%), in AML 29 out of 39 (74%) while in ALL 13 out of 25 (52%), Aven 
expression was (40.6%) in acute leukemia equally expressed in AML 16 out of 39 
(41%) while in ALL 10 out of 25 (40%).(table,1). 
 
           Patients were categorized into 3 groups based on DNA fragmentation were by 
group I DNA fragmentation found in (D 1 or D1+D2), group II found in 
(D1+D2+D3), group III where fragmentation was(D1+D2+D3+D4or/andD5). 
Apoptosis in group III was found in 13 out of 22 (59%) ALL and 15 out of 34 
(44.1%)  AML patients. 
 
          Out of 35 Aven negative AL, 24 (68.6%) were in group III (the best group) (P = 
0.007) table (2). absence of Survivin did not contribute as much. In fact 18 out of 31 
(58%) of group III were Survivin positive (P= 0.1) table (3). None of the concordant 
both positive Survivin and Aven were in group III (the good 5 day fragmentation), 
this was statistically highly significant (P< 0.001) relation table (4). 
 
          Survivin was statistically related to CD7 expression (P<0.001) in AML only 
table (5), while Aven was statistically related to CD34 expression (P<0.014) in both 
ALL and AML table (6). However Survivin expression was not significant related 
with CD33 in AL and Aven expression was not significant with neither CD7 nor 
CD33.Aven was statistically correlated to alkaline phosphatase (P< 0.036). 
          There was a clear dissociation of expression of Aven and Survivin in acute 
leukemia 44/64(68.7%), that is to say these two markers tend not to be expressed 
together. This dissociation is statistically significant (P=0.03) in AML and near 
significant (p=0.07) in ALL table (7).  
            After afollow up period ranged between 1-21 months for all our acute 
leukemic patients, the mean over all survival was 18.41± 18.30 months (95% 
confidence interval).the median survival was 7.0±5.3 months. The Survival analysis 
carried out in all our acute leukemic patients regarding the expression of the studied 
markers revealed a significantly higher overall survival in patients who were Aven 
negative (P <0.001) figure (4).  
 
            A statistical significant higher over all survival was found in each AML & 
ALL group and Aven negative patients (P 0.002, 0.007) respectively figure (5-6). On 
the other hand there was no significant difference neither in (ALL, AML nor AL) 
patients in relation with Survivin expression. Survival analysis revealed a very higher 
significant short over all survival in all AL and AML patients who were positive for 
both Aven and Survivin (P <0.001) for both figure (7-8). Unfortunately over all 
survival can not be done in ALL patients who expressed both Aven and survivan due 
to the small number (only 3 patients). Survival analysis was carried out in all our 
acute leukemia patients regarding DNA fragmentation there was highly significant 
over all survival in patients who have good DNA response (group 3) (P < 0.001) 
figure (9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
 
According to the registry of the National Cancer Institute, Cairo University, acute 
leukemia is the 4th most common cancer among males and the 3rd most common 
cancer among females. Acute lymphoblastic leukemia (ALL) constitutes about 80% 
of childhood cases whilst acute myeloid leukemia (AML) constitutes about 80% of 
adult cases. In the present study we evaluated the expression of survivin and aven 
status of CD7, CD34, CD33 cell surface markers as well as the DNA fragmentation 
(before and during initial induction) in blast cells separated from peripheral blood for 
AML and ALL patients as well as 20 healthy volunteers. The results were correlated 
to clinical and hematological findings and response to therapy. The patients were 
followed up for up to1- 21 months. 
 
Regarding the survivin, 74.4% of the AML cases were +ve while 52% of the ALL 
cases were +ve. The expression of survivin was significantly associated with the 
expression of CD7 in AML (P =0.001), while in ALL; survivin did not show any 
significance when correlated with CD7, CD33&CD34.Unlike the turkish group ( ) 
where they found a significant correlation between the expression of both CD7 and 
survivin in all acute leukemia (Both AML and ALL) cases. It is known that CD7 
mediated cell activation may be transduced via the lipid kinase phosphatidyl inositol 
3-kinase (Pi3-kinase), at the same time the up-regulation of survivin occurs through 
the activation of Pi3-kinase. So, the activation is common for both survivin up 
regulation ( - ) and CD7 activation ( ).Thus the pathway CD7,Pi3AKT&survivin 
is most probably operational in Egyptian AML only. 
 
In the present study we have evaluated the patients response to therapy (cell apoptosis 
before & during initial induction of chemotherapy) using DNA fragmentation of 
peripheral blood blast cells, where we collected blood samples from the 56 patients at 
days 1,2,3,4 and 5, the DNA was extracted and agarose gel electrophoresis was done. 
 
     We did not find significance between survivin expression and DNA fragmentation 
where the P value was border line (P= 0.1). More studies are clearly needed on a 
larger number of samples to reach a final conclusion. Unlike survivin the DNA 
fragmentation with Aven was highly significant relation (P=0.007) where, there was 
an inverse relation between the expression of Aven and DNA fragmentation. 
 
This means that when aven is expressed, chemotherapy induced apoptosis is 
abolished. For our knowledge, this is the first study that correlates the expression of 
aven with the DNA fragmentation in acute leukemia. Aven was correlated, CD7, 
CD33, CD34. When aven was correlated to CD34 we found that aven was 
significantly correlated to the expression of CD34 (P =0.014), where both markers are 
important indicators of poor prognosis. This finding is similer to that found by ( ) in 
the Turkish population. 
 
In acute leukemia, there is a tendency that these two inhibiters of apoptosis are not 
expressed together. Most of the cases 44/64 were either positive for survivin & 
negative for aven (30/64) or negative for survivin & positive for aven (14/64). In 
AML 27/39 were having either marker aven negative and survivin positive, 
9/39(23%) were concordant both positive, 3/39(7.6%) were concordant both negative. 
There was a significant dissociation (P=0.03) between the expression of aven and 
survivin in AML, while in ALL there is a borderline significant dissociation (P = 
0.07%) between the expression of aven and survivin, however, increasing the number 
of patients might bring it to the significant level, up to our best knowledge, this is the 
first report to establish such a relationship.  
 
In the present study , patients were followed up for 1-21 months and when correlated 
to their aven status, we found that aven significantly affects the overall survival of the 
patients (P<0.001).However, survivin did not correlate significantly to OS in acute 
leukemia. Also, combined expression of both IAPs markers correlated significantly to 
survival (P< 0.001). When10 out of 12 cases positive for both markers were subjected 
for DNA fragmentation, all the 10 patients had reduced DNA fragmentation (P 
0.001). This could be explained by a synergistic inhibitor of apoptosis effect when 
both markers are expressed .This is the only report on the relationship between the 
expression of Aven , survivin and DNA fragmentation in acute leukemia. 
 
From the present study we can conclude that: 
1 The association between aven, CD34 & alkaline phosphatase which are strong 
negative prognostic factors in acute leukemia suggests that aven is an 
independent candidate parameter to determine the poor prognosis in acute 
leukemia. 
2-Aven seems to be more important as an inhibitor of apoptosis than survivin in acute 
leukemia. 
3- Aven and survivin could be considered as two independent anti apoptotic pathways 
that could act separately to inhibit apoptosis in the leukemic patients.  
4- The presence of both Aven & survivin confers a survival disadvantage & a 
significantly worse DNA fragmentation pattern, thus suggesting a synergistic 
inhibition of apoptosis when present together.  
5- The association between higher expression of survivin and CD7 which is a 
strong negative prognostic factor in acute leukemia suggests that survivin is a 
marker for poor prognosis in acute leukemia & the pathway CD7 Pi3AKT and 
survivin  is operational in AML. 
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Table (1): comparison between Survivin & Aven expression in    acute leukemic 
patients: 
 
 
P 
Value 
ALL 
(no 25) 
 
AML 
(no 39) 
 
Item 
0.06 
13 
(52%) 
29 
(74.4 %) 
Survivin 
+ 
0.935 
10 
(40%) 
16 
(41%) 
Aven 
+ 
       
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (2): Comparison between Aven expression and DNA fragmentation groups in 
acute leukemia:  
 
Group 
 
 
Aven 
positive 
 
Aven 
negative 
 
P value 
 
 
Group 1 
 
 
      9 
(42.9%) 
     3 (8.6%)  
 
 
 
0.001 
 
Group2       5 
(23.8%) 
     8 
(22.9%) 
Group 3       7   
(33.3) 
24     
(68.6%) 
              
 
 
 
  
 
 
 
Table (3): Comparison between Survivin expression and DNA fragmentation groups in 
acute leukemia:       
 
Group 
 
 
survivin 
positive 
 
survivin 
negative 
 
P value 
 
 
Group 1     11 
(29.7%) 
       1  
(5.3%) 
 
 
 
0.1 
 
Group2       8 
(21.6%) 
       5 
(26.3%)  
Group 3       18 
(48.6%) 
13     
(68.4%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table (4): Comparison between concordant double expression of both Survivin & Aven 
cases and all otherwise cases and DNA fragmentation in acute leukemia:  
 
Group 
 
 
   Both* 
positive 
 
**otherwise 
 
P value 
 
 
Group 1 9 
 (90%) 
3 
(6.5%) 
 
 
 
0.000 
 
Group2 1  
(10%) 
12 (26.1%) 
Group 3 0  
(0%) 
31    (67.4%) 
*Both positive= cases expressing both aven & survivin. 
**otherwise= other combinations either both negative or expressing either. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table (5): Relation between the expression of Survivin and CD7 in acute leukemia 
 
Items 
 
Survivin  
Positive  
Survivin  
Negative 
 
P value 
 
AML 
CD7 Positive 
 
CD7 Negative 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
0.001            
ALL 
  
CD7 Positive 
 
CD7 Negative 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
NS 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table (6): Relation between the expression of Aven and CD34 in acute leukemia 
(ALL&AML) 
 Aven  positive Aven negative P Value 
CD34 positive 17 (56.7%) 13 (43.3%)  
0.014 CD34 negative 8 (25.8%) 23 (74.2%) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (7) : Relation between the expression of both (Survivin and Aven) in ALL and 
AML. 
 SURVIVIN 
+ve                             -ve 
Total P value 
AML  
Aven         + 
Aven         - 
 
 9 
20 
 
 
        7 
        3 
 
 
 
39 
 
 
0.031 
ALL 
Aven         + 
Aven         - 
 
           3 
         10 
 
       7 
       5 
 
 
         
         
25 
                 
 
 
0.072 
Total 42 22 64  
 
 
 
 
                         Figure (2): shows PCR product of Survivin (305 bp) and 
Aven 
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 (252bp): 
Lanes 2,3,4,5,6,7: show Aven expression of AL patients. 
Lanes 9,10,11,12,13,14,15: show Survivin expression. 
Lane 1: Marker ladder (100-1000). 
 
 
 
Figure (2): shows PCR product of Survivin (305 bp) and Aven 
 
 
                                1     2    3    4      5    6  7      8    9    10  11   12 13 14   15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (252bp): 
Lanes 2,3,4,5,6,7: show Aven expression of AL patients. 
Lanes 9,10,11,12,13,14,15: show Survivin expression. 
Lane 1: Marker ladder (100-1000). 
 
 
DNA fragmentation at 200bp Figure (3):     
  
 1                 2                  3                  4                 5                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lanes  1 , 2 : Apoptosis by agarose gel electrophoresis before therapy. 
           Lanes 3,4: Apoptosis by agarose gel electrophoresis, 24 hours after therapy . 
              Lane 5: Marker ladder (100 -1000). 
 
  
Figure (4): overall survival and Aven in acute leukemia.  
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Figure (5): overall survival and Aven expression in AML. 
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Figure (6) overall survival and Aven expression in ALL. 
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Figure (7): overall survival with both Aven and Survivin positive in acute                           
leukemia. 
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Figure (8): overall survival with both Aven and Survivin positive in AML. 
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Figure (9): overall survival with DNA fragmentation in acute                           
leukemias:  
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